Targeted therapy in gynecologic cancers: Ready for prime time?  by Seoud, Muhieddine et al.
International Journal of Gynecology and Obstetrics 131 (2015) S150–S152
Contents lists available at ScienceDirect
International Journal of Gynecology and Obstetrics
j ourna l homepage: www.e lsev ie r .com/ locate / i jgoFIGO CANCER REPORT 2015Targeted therapy in gynecologic cancers: Ready for prime time?Muhieddine Seoud a, Elisabeth Åvall Lundqvist b, Keiichi Fujiwara c
a Department of Obstetrics and Gynecology, Gynecologic Oncology, American University of Beirut Medical Center, Beirut, Lebanon
b Department of Oncology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
c Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Japan1. Introduction: Unmet need
Each year, around 225 000 women are diagnosed with ovarian can-
cer and over 140 000die [1]. Despite the recent advances in understand-
ing the role of proper staging in early cases, maximal debulking efforts,
and new modes and route of adjuvant (including intraperitoneal and
dose-dense regimen), neoadjuvant, and palliative chemotherapeutic in-
terventions, recurrences are inevitable and survival rates are still dismal
in the advanced stages.
Similarly, cervical cancer remains a major killer of women in low-
resource countries and in women of low socioeconomic status in high-
resource countries. In 2012, 528 000 women were affected and
226 000 died of their disease [1]. Despite the recent advances in primary
prevention (HPV vaccination) and secondary prevention (screening by
cytology and/or HPV testing and subtyping), most women in low-
resource countries have no access to either vaccination or screening,
and still present at a late stage.
Although early-stage and locally advanced cancers may be cured
with radical surgery, chemoradiotherapy, or both, these modalities are
scare in low-resource countries. Moreover, patients with metastatic
cancers and those with persistent or recurrent disease after platinum-
based chemoradiotherapy have limited options [2,3]. In both of these
cancers, new forms of therapy are needed.
Increasing knowledge of the genetic basis for various cancers has led
to the development of new drugs that are tailored to these speciﬁc can-
cer pathways, while sparing normal cells and reducing the toxic adverse
effects of classical chemotherapy.
2. Ovarian cancer
New treatment options forwomenwith advancedovarian cancer in-
clude antiangiogenic drugs and poly (ADP-ribose) polymerase (PARP)
inhibitors. Others include vaccines and anti-PD-1/PD-L1 therapies.
2.1. Antiangiogenic therapies
Angiogenesis is the formation of new blood vessels from pre-
existing ones. A balance between pro- and antiangiogenic signaling
pathways is maintained so that angiogenesis is only switched on
when required for healing.
This pathway is governed by the vascular endothelial growth factor
receptors (VEGFRs). Three VEGFRs (VEGFR 1, 2, and 3) mediate thehttp://dx.doi.org/10.1016/j.ijgo.2015.06.012
0020-7292/© 2015 Published by Elsevier Ireland Ltd. on behalf of International Federation of
(http://creativecommons.org/licenses/by-nc-nd/4.0/).effects of their ligands; these ligands comprise a family of growth fac-
tors, VEGF A through E, that induce proliferation andmigration of endo-
thelial cells—the primary cell type involved in the formation of new
blood vessels.
In principle, once a tumor exceeds 1 mm in diameter it cannot re-
ceive adequate nutrients or oxygen from surrounding tissues by diffu-
sion alone and it must then stimulate new blood vessel formation to
support further growth [4]. Tumor cells induce an angiogenic switch
in response to hypoxia and genetic alterations and produce angiogenic
growth factors that promote proangiogenic signaling pathways, such
as the VEGF pathway. The new blood vessels help the tumor grow and
provide potential routes for spread. VEGF signaling can be blocked at
several levels.
Targeted therapies differ from chemotherapy because they do not
induce direct cell kill but prolong time to progression. Objective
responses are therefore, in general, low, but progression-free survival
and overall survival can be prolonged anyway. In addition, since
targeted therapies affect disease-speciﬁc alterations and not normal tis-
sues, they can be used as maintenance therapy.
In 2004, the US Food and Drug Administration (FDA) approved
bevacizumab, a monoclonal antibody targeting VEGF-A, for the ﬁrst-
line treatment of metastatic colorectal cancer in combination with
standard chemotherapy. More recently, the US Gynecologic Oncology
Group (GOG) 218 trial [5] and the European International Collaborative
Ovarian Neoplasm (ICON) 7 trial [6] investigated the addition of
bevacizumab to conventional chemotherapy in high-risk metastatic
ovarian cancer with maintenance bevacizumab following chemothera-
py. The two trials showed a signiﬁcant beneﬁt on progression-free
survival and bevacizumab was approved by the European Medicines
Agency (EMA). The EMA also approved the use of bevacizumab in
platinum-sensitive recurrent ovarian cancer based on the OCEANS
trial [7], which showed doubling of the progression-free survival. In ad-
dition, the FDA and the EMA also approved the use of bevacizumab in
patients with recurrent, platinum-resistant ovarian cancer based on
the phase III AURELIA trial [8], which demonstrated that bevacizumab
with chemotherapy reduced the risk of disease progression by52% com-
pared with chemotherapy alone.
Currently, optimizing the use of bevacizumab is being investigated
in several trials, including the optimal duration (AGO-OVAR-17/
BOOST), and the optimal combination with dose-dense chemotherapy
(GOG 262, OCTAVIA), with intraperitoneal chemotherapy (GOG 252),
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sis pathways are active in ovarian cancer, other investigators are
assessing predictive tumor markers using either clinical characteristics
from the major trials or certain biological tumor markers, such as gene
immune signatures [9], histological subtypes such as the proliferative
and mesenchymal subgroups [10], and Ang 1 and Tie2 concentrations.
Other active angiogenic agents are also under investigation; for exam-
ple, trebananib, which blocks Ang 1 and 2 by preventing their binding
to the Tie2 receptor differs from VEGF-targeted agents in terms of ad-
verse effects, such as bowel perforation and hypertension. Its use was
associated with improvements in progression-free survival in patients
with recurrent epithelial ovarian cancer. However, other research in-
volves targeting the VEGF-receptor signaling rather than its ligand.
Antiangiogenic therapy faces a number of barriers that limit its
potential. The clinical beneﬁt of these agents has been modest and
they are associated with high costs, which signiﬁcantly limit their use
in most low-resource countries, and signiﬁcant adverse effects such as
hypertension, thrombotic events, and bowel perforation. Moreover,
the role of angiogenesis in tumor development is clearly vastly more
complex than originally believed and the interaction between the
tumor, the vasculature, and the tumor microenvironment remains
poorly understood.
Other agents that have been investigated with variable responses
are pazopanib and cediranib. A phase II open-label study of pazopanib
(given 800mgdaily, orally)was conducted in 36womenwith recurrent
ovarian cancer and an elevated CA125, who had previously had a com-
plete CA125 response to platinum-based chemotherapy [11]. The au-
thors reported that 11 (31%) women had a CA125 response, and
progression-free survival at 6 months was 17% (95% CI, 6%−33%). A
phase II study of daily cediranib in 47 women with recurrent ovarian
cancer found themedian progression-free survivalwas 5.2months [12].
2.2. PARP inhibitors
PARP inhibitors rely on the sensitivity of cells containing a defect in
homologous recombination pathways to PARP inhibition (e.g. those
with BRCA mutations), which results in the death of target tumor cells
while sparing normal cells. Three ongoing studies are currently investi-
gating this sensitivity: ARIEL, SOLO, and NOVA. Recently, both the FDA
and EMA approved olaparib, a PARP inhibitor, as amaintenance therapy
to prevent recurrence in platinum-sensitive ovarian cancer on the basis
of the phase III trial SOLO [13]. The manufacturer also submitted addi-
tional data supporting the use of olaparib in patients with BRCA-
mutated ovarian cancer who have already received three or more
chemotherapy treatments. Two other phase 3 trials are underway: the
SOLO2 trial is evaluating olaparib versus placebo as a maintenance
therapy; and the SOLO3 trial is evaluating olaparib compared with
standard chemotherapy for relapsed disease.
2.3. Other biologically active agents
Immunotherapy using anti-PD-1–therapies (nivolumab) in relapsed
platinum-resistant ovarian cancer resulted in a dose-dependent re-
sponse rate of 20%−33% [14]. This can be used either with or without
an anti-CTLA-4 antibody (ipilimumab). Other research involves using
mTOR inhibitors, for clear cell cancers of the ovary and MEK inhibitors
for low-grade serous cancers [15,16].
3. Cervical cancer
Tumor neovascularization, as reﬂected by an increased microvessel
density and strong immunostaining for the endothelial-cell marker
(CD31), is associated with an aggressive course in cervical cancer
[2–4]. Moreover, patients with high-grade cervical dysplasia and
invasive carcinoma have increased expression of VEGF and hypoxia-
inducible factor 1α (HIF-1α) [17]. Invasion is noted when VEGF isup-regulated. On the one hand, oncogenic HPV subtypes enhance
HIF-1α protein production and VEGF expression, while on the other,
VEGF expression is diminished by silencing HPV E6 mRNA but not
when p53 is silenced, which means that E6 induces VEGF through a
p53-independent mechanism [18]. In addition, HIF-1α activity en-
hanced by E7 maps to its C-terminal and correlates with displacement
by E7 of the histone deacetylases HDAC1, HDAC4, and HDAC7 [19].
Recently, the FDA and EMA approved bevacizumab in combination
with paclitaxel plus either cisplatin or topotecan as a treatment for
patients with persistent, recurrent, or metastatic cervical cancer, based
on the extension of overall survival in the GOG 240 study [20].
Bevacizumab combined with chemotherapy increased overall survival
by 3.7months, from12.9 to 16.8months, comparedwith chemotherapy
alone. Although this may be considered a small gain, it is hoped that
with the development of newer agents, quality overall survival may
be improved. Other VEGF and non-VEGF mediated compounds are
currently under investigation; for example, pazopanib (a tyrosine
kinase inhibitor that targets the VEGF receptor) and sorafenib (a
multikinase inhibitor) are two such agents [21]. However, data are lack-
ing on vascular disrupting agents (e.g. vadimezan) and agents that
inhibit angiogenesis through non-VEGF-dependent pathways (e.g. the
Tie2–angiopoietin-2 pathway). In addition, agents targeting non-
angiogenic signal-transduction pathways including Wee1 checkpoint
inhibitors and Notch γ-secretase inhibitors may be promising.
4. Other gynecologic cancers
The role of biologically active agents is less studied in other gyneco-
logic cancers. Unlike ovarian or cervical cancers, almost 90% of women
with endometrial cancer are treated by primary surgery with ﬁve-year
survival rates of over 70% [22]. Even when endometrial cancer recurs,
it can be salvaged by a combination of surgery and radiotherapy. How-
ever, despite advances in radiotherapy, surgery, and chemotherapeutic
strategies, the prognosis of women with recurrent or advanced endo-
metrial cancer is poor, with a median overall survival of approximately
7–10 months [23–25].
There is a pressing need to improve current treatment strategies.
In endometrial cancer, the expression levels of VEGF correlate well
with prognosis [26]. In a phase II trial of single-agent bevacizumab in
recurrent endometrial cancer, 40.4% of patients had a progression-free
survival of at least 6 months [27]. Numerous other targeted agents
have been investigated with variable disappointing results in recurrent
and metastatic endometrial cancer. These included aﬂibercept (VEGF
Trap-Eye) with a high-afﬁnity binding to VEGF-A, VEGF-B, and pla-
cental growth factor [28,29]; thalidomide with antiangiogenesis effect
[30]; geﬁtinib and erlotinib, two tyrosine kinase inhibitors [31,32];
cetuximab, a monoclonal antibody against epidermal growth factor re-
ceptor (EGFR) [33]; trastuzumab and lapatinib, both EGFR type 2
(HER2)-related inhibitors that affect signal transduction [34–36]; and
temsirolimus and ridaforolimus, which block the phosphoinositide 3-
kinase/AKT/mTOR pathway [37,38]. Other kinase inhibitors studied
are sunitinib, brivanib, sorafenib, and imatinib [39]. Other drugs target
epigenetic regulation of various cancer genes [40,41]. Epigenetic regula-
tions may be particularly important in type I endometrial cancer.
The generally lower response rates of various targeted agents as
compared with standard chemotherapy (43.3%−87%) [41–44] may be
due to the multiplicity of carcinogenetic pathways and associated
genes. Thus suppression of a single molecule may not be enough. Resis-
tance may be circumvented using combinations of molecular-targeted
drugs, and through the use of combination with current chemothera-
peutic agents and/or hormonal therapy.
5. Conclusion
The role of targeted therapy in gynecological cancers, like in many
other cancers, remains elusive. The last decade has seen signiﬁcant
S152 M. Seoud et al. / International Journal of Gynecology and Obstetrics 131 (2015) S150–S152progress in deﬁning the role of various genetic pathways and the use of
relevant agents. Few successes include the use of antiangiogenesis
agents and PARP inhibitors in ovarian cancer. The use of various clinical
and biochemicalmarkers will help limit their use to thosewhowill ben-
eﬁt the most.
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